product
31 articles in this category (Page 2 of 2)
EarningsProductGuidance
Stevanato Group (STVN): Q4 Earnings Beat and GLP-1 Tailwinds Drive 21-Day Bullish Outlook Despite Cash Flow Risks
Stevanato Group's Q4 earnings beat and strong GLP-1 revenue growth signal a continued upward trajectory, though negative free cash flow warrants caution.
STVN
Read moreregulatoryproductearnings
ImmunityBio (IBRX) 21-Day Outlook: Increase Expected Amidst Global ANKTIVA Approvals Despite Overbought Technicals
ImmunityBio's massive 700% revenue growth and new international ANKTIVA approvals signal upside potential, though overbought technicals and deep negative margins cap confidence.
IBRX
Read more